Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Canopy Growth synthesizes cannabinoid CB1 and CB2 receptor ligands

Feb. 9, 2021

Onxeo partners with Institut Curie to study AsiDNA with radiotherapy in pediatric high-grade glioma

Feb. 9, 2021

Phase I trial of IDE-397 for solid tumors with MTAP deletion cleared to begin in U.S.

Feb. 8, 2021

FDA grants accelerated approvals of Ukoniq for marginal zone lymphoma and follicular lymphoma

Feb. 8, 2021

Single-cell resolution reveals cell type, targets, for neuroblastoma

Feb. 8, 2021

Scenic Immunology synthesizes new QC and/or QPCTL inhibitors

Feb. 8, 2021

Pfizer presents new TLR agonists

Feb. 8, 2021

Ono Pharmaceutical divulges KDM5A inhibitors

Feb. 8, 2021

China NMPA approves phase III trial of orelabrutinib with R-CHOP for MCL

Feb. 5, 2021

CEACAM7 is a therapeutic target for CART therapy in PDAC

Feb. 5, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...